Serum CD44 levels and overall survival in patients with HER2-positive breast cancer

被引:19
|
作者
Baek, Jong-Min [1 ]
Jin, Quanri [1 ]
Ensor, Joe [2 ]
Boulbes, Delphine R. [1 ]
Esteva, Francisco J. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA
基金
美国国家卫生研究院;
关键词
Breast cancer; Soluble CD44; HER2; Survival; NON-HODGKINS-LYMPHOMA; SOLUBLE CD44; COLORECTAL-CANCER; PROGNOSTIC-SIGNIFICANCE; MESSENGER-RNA; COLON-CANCER; VARIANT; EXPRESSION; CARCINOMA; METASTASIS;
D O I
10.1007/s10549-011-1691-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
CD44 is an adhesion molecule involved in tumor cell invasion and metastasis. The function of CD44 in breast cancer is not understood completely, or is its role as a predictive or prognostic factor. In this study, we tested for the hypothesis that the concentration of soluble CD44 (sCD44) in serum is correlated with clinicopathological factors, especially HER2, and survival in patients with breast cancer. We retrospectively identified 110 patients with breast cancer who had been treated at The University of Texas MD Anderson Cancer Center (MDACC) from September 2001 to May 2004. Sera were collected before definitive surgery in patients with stage I or II breast cancer, before initiation of neoadjuvant chemotherapy (if indicated) for patients with stage I-III breast cancer, and before initiation of systemic therapy in patients with stage IV breast cancer. sCD44 levels were determined using an enzyme-linked immunosorbent assay. The median age at diagnosis was 51 years (range, 28.6-87.1 years). sCD44 concentration was correlated with tumor stage (P = 0.0308). sCD44 serum concentration did not predict pathological response in patients treated with neoadjuvant chemotherapy. Among patients with distant metastases, sCD44 levels were significantly higher in patients with liver involvement than in patients with metastases at other sites. The overall survival rate did not differ between patients with high sCD44 concentration and patients with low sCD44 concentration. However, sCD44 concentration was a significant predictor of overall survival for patients with HER2-positive breast cancer, while no difference in overall survival rates was observed in patients with HER2-negative breast cancer. To the best of our knowledge, this is the first study to show an association between circulating sCD44 levels and survival in HER2-positive breast cancer patients. Our results suggest a role for sCD44 as a prognostic marker. Furthermore, sCD44 level may offer a new clinical therapeutic target in HER2-positive breast cancer.
引用
收藏
页码:1029 / 1036
页数:8
相关论文
共 50 条
  • [1] Serum CD44 levels and overall survival in patients with HER2-positive breast cancer
    Jong-Min Baek
    Quanri Jin
    Joe Ensor
    Delphine R. Boulbes
    Francisco J. Esteva
    [J]. Breast Cancer Research and Treatment, 2011, 130 : 1029 - 1036
  • [2] CD44 expression contributes to trastuzumab resistance in HER2-positive breast cancer cells
    Boulbes, Delphine R.
    Chauhan, Gaurav B.
    Jin, Quanri
    Bartholomeusz, Chandra
    Esteva, Francisco J.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2015, 151 (03) : 501 - 513
  • [3] CD44 expression contributes to trastuzumab resistance in HER2-positive breast cancer cells
    Delphine R. Boulbes
    Gaurav B. Chauhan
    Quanri Jin
    Chandra Bartholomeusz
    Francisco J. Esteva
    [J]. Breast Cancer Research and Treatment, 2015, 151 : 501 - 513
  • [4] Radiolabeled trastuzumab biodistribution and serum HER2 levels in HER2-positive metastatic breast cancer patients
    Perik, Patrick J.
    Lub-de Hogge, Marjolijn N.
    Gietema, Jourik A.
    Jager, Piet L.
    Kosterink, Jos G.
    de Korte, Sander A.
    van Veldhuisen, Drik J.
    van der Graaf, Winette T.
    Sieijfer, Drik T.
    de Vries, Elisabeth G.
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 14 - 14
  • [5] The impact of neoadjuvant chemotherapy on overall survival in patients with early-stage HER2-positive breast cancer
    Champion, Nicholas
    Azab, Basem
    Abeysekera, Aravinda
    Kim, Sara
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (SUPPL 1) : 201 - 201
  • [6] The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer – a systematic review
    Diogo Mendes
    Carlos Alves
    Noémia Afonso
    Fátima Cardoso
    José Luís Passos-Coelho
    Luís Costa
    Sofia Andrade
    Francisco Batel-Marques
    [J]. Breast Cancer Research, 17
  • [7] The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer - a systematic review
    Mendes, Diogo
    Alves, Carlos
    Afonso, Noemia
    Cardoso, Fatima
    Passos-Coelho, Jose Luis
    Costa, Luis
    Andrade, Sofia
    Batel-Marques, Francisco
    [J]. BREAST CANCER RESEARCH, 2015, 17
  • [8] Clinicopathological analysis of CD44 expression in HER2 positive invasive breast cancer
    Sanaat, Z.
    Dolatkhah, R.
    Roosta, Y.
    Nikhanfar, A. R.
    Fakhrjou, A.
    [J]. BREAST, 2019, 44 : S25 - S26
  • [10] Anchoring of hyaluronan glycocalyx to CD44 reduces sensitivity of HER2-positive gastric cancer cells to trastuzumab
    Chen, Si
    Zhang, Guoliang
    Liu, Yiwen
    Yang, Cuixia
    He, Yiqing
    Guo, Qian
    Du, Yan
    Gao, Feng
    [J]. FEBS JOURNAL, 2024, 291 (08) : 1719 - 1731